描述 |
Trihexyphenidyl盐酸盐是抗毒蕈碱类的抗帕金森剂, 结合至M1毒蕈碱受体。 |
||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
相关类别 |
|
||||||||||||
溶解度 |
体外:
DMSO:11.66 mg / mL(34.50 mM;需要超声波和加热)
|
||||||||||||
储备液 |
|
||||||||||||
存储 |
|
||||||||||||
运输 |
室温;可能会有所不同 |
||||||||||||
SMILES |
OC(C1=CC=CC=C1)(C2CCCCC2)CCN3CCCCC3.[H]Cl |
||||||||||||
相关活性 小分子 |
卡巴胆碱 | 氢溴酸达非那新 | 氢溴酸槟榔碱 | 盐酸哌仑西平 | 甘罗溴铵 | 咪达那新 | 甲磺酸苯扎托品 | 诺美林草酸盐 | Batefenterol | 氯贝胆碱 | 盐酸西维美林 | 奥替溴铵 | 索利那新 | VU0467154 | 山莨菪碱 |
沸点 | 447.9?C at 760mmHg |
---|---|
熔点 | 258.5?C |
分子式 | C20H32ClNO |
分子量 | 337.927 |
闪点 | 211?C |
精确质量 | 337.217255 |
PSA | 23.47000 |
LogP | 5.07040 |
外观性状 | solid | white |
储存条件 |
通风低温干燥; 与库房食品原料分开存放。 |
水溶解性 | H2O: soluble |
计算化学 |
1.疏水参数计算参考值(XlogP):无 2.氢键供体数量:2 3.氢键受体数量:2 4.可旋转化学键数量:5 5.互变异构体数量:无 6.拓扑分子极性表面积23.5 7.重原子数量:23 8.表面电荷:0 9.复杂度:314 10.同位素原子数量:0 11.确定原子立构中心数量:0 12.不确定原子立构中心数量:1 13.确定化学键立构中心数量:0 14.不确定化学键立构中心数量:0 15.共价键单元数量:2 |
盐酸苯海索毒性英文版
|
危害码 (欧洲) |
Xn |
---|---|
风险声明 (欧洲) |
R22 |
安全声明 (欧洲) |
S36 |
危险品运输编码 | 3249 |
WGK德国 | 3 |
RTECS号 | TN2625000 |
包装等级 | III |
危险类别 | 6.1(b) |
海关编码 | 2933990090 |
海关编码 | 2933399090 |
---|---|
中文概述 | 2933399090. 其他结构含非稠合吡啶环的化合物. 增值税率:17.0%. 退税率:13.0%. 监管条件:无. 最惠国关税:6.5%. 普通关税:20.0% |
申报要素 | 品名, 成分含量, 用途, 乌洛托品请注明外观, 6-己内酰胺请注明外观, 签约日期 |
Summary | 2933399090. other compounds containing an unfused pyridine ring (whether or not hydrogenated) in the structure. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0% |
Gingival pain: an unusual side effect of ziprasidone. BMJ Case Rep. 2013 , doi:10.1136/bcr-2012-007577, (2013)
The patient is a 52-year-old man with schizophrenia who developed severe, unremitting gingival pain after his ziprasidone dosage was increased from 80 to 120 mg. His physical examination and laborator…
|
|
A misguided ‘pill in the pocket’ approach with flecainide leading to cardiac arrest. BMJ Case Rep. 2012 , doi:10.1136/bcr-2012-006868, (2012)
|
|
DYT16: the original cases. J. Neurol. Neurosurg. Psychiatr. 83(10) , 1012-4, (2012)
DYT16 is an autosomal recessive dystonia-parkinsonism due to putative mutations at PRKRA gene. The aim of this study was to describe clinical features providing video documentation of patients with DY…
|
|
1-(3-cyclohexyl-3-hydroxy-3-phenylpropyl)piperidinium chloride |
1-Cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-olhydrochlorid |
Trihexy |
1-Cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride (1:1) |
UNII:AO61G82577 |
1-Cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-olhydrochlorid |
1-cyclohexyl-1-phenyl-3-(1-piperidinyl)-1-propanol hydrochloride |
1-Piperidinepropanol, α-cyclohexyl-α-phenyl-, hydrochloride (1:1) |
pacitane |
Broflex |
(-)-α-Cyclohexyl-α-phenyl-1-piperidinepropanol hydrochloride |
1-cyclohexyl-1-phenyl-3-piperidin-1-ylpropan-1-ol hydrochloride |
pipanol |
1-Cyclohexyl-1-phenyl-3-(1-piperidinyl)-1-propanol hydrochloride (1:1) |
1-Piperidinepropanol, α-cyclohexyl-α-phenyl-, hydrochloride, (+)- |
tremin |
EINECS 205-614-4 |
Benzhexol HCL |
Parkan |
paralest |
peragit |
Sedrina |
(+)-α-Cyclohexyl-α-phenyl-1-piperidinepropanol hydrochloride |
cyclodol |
a-Cyclohexyl-a-phenyl-1-piperidinepropanol Hydrochloride |
MFCD00058212 |
trihexylphenidyl HCl |
1-Cyclohexyl-1-phenyl-3-(piperidin-1-yl)propan-1-ol hydrochloride |
1-cyclohexyl-1-phényl-3-pipéridin-1-ylpropan-1-ol chlorhydrate |
D,L-Trihexyphenidyl Hydrochloride |
1-Piperidinepropanol, α-cyclohexyl-α-phenyl-, hydrochloride, (-)- |
Trihexyphenidyl hydrochloride |